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Background: Offspring born following maternal gestational diabetes are at risk of excessive childhood weight gain
and Type 2 diabetes in childhood, which in turn is associated with an increased rate of hypertension.
We aimed to determine the systolic and diastolic blood pressure at two years of age in a cohort of children
exposed to gestational diabetes mellitus using data from the MiG trial of metformin use in gestational diabetes. The
secondary aim was to analyze these data by randomization of treatment to insulin or metformin.
Methods: The offspring of women who had gestational diabetes and had been assigned to either open treatment
with metformin (with supplemental insulin if required) or insulin in the MiG trial were followed up at 2 years of age.
Oscillometric measurement of BP in the right arm was performed by a researcher using an appropriately sized cuff.
Results: A total of 489 measurement blood pressure measurements were obtained in 170 of the 222 children who
were seen at a median (range) age of 29 (22–38) months corrected gestational age. At the time of assessment the
mean (SD) weight and height was 13.8(2) kg and 90 (4.2) cm respectively. For the whole group the mean (SD)
systolic pressure was 90.9 (9.9) mmHg and mean (SD) diastolic pressure was 55.7 (8.1) mmHg. No difference was
found between the metformin and insulin treatment arms. In a regression model, height and weight were only two
factors associated with the levels of systolic blood pressure. For each additional kg the systolic blood pressure
increased by 1.0 mmHg. For each additional cm of height the systolic blood pressure increased by 0.42 mmHg.
Conclusions: Blood pressure data was obtained at approximately two years of age in a substantial cohort of
children whose mothers received treatment for GDM. These novel data compare favorably with published norms.
Clinical Trials Registry: This study was registered under the Australian New Zealand Clinical Trials Registry
(ACTRN12605000311651).
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Fetal exposure to high circulating blood glucose associ-
ated with maternal diabetes can result in major child-
hood effects for the offspring, particularly increased
rates of obesity and Type 2 diabetes. Although these ef-
fects have been known for some time, there has been
more of a focus on the topic over the last decade.* Correspondence: malcolmb@adhb.govt.nz
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unless otherwise stated.Indeed, a recent review on infants born to mothers with
gestational diabetes mellitus (GDM) highlighted both
the increased incidence of GDM, associated with the
obesity pandemic, and the potential threat to global
health from long term and transgenerational effects [1].
In a landmark study of pregnancy outcome in Pima
Indians, children born to mothers with Type 2 diabetes
or gestational diabetes mellitus (GDM) were larger for
gestational age at birth and heavier at five years of age
compared with those born to non-diabetic women [2].
Subsequent studies have confirmed that exposure tohis is an Open Access article distributed under the terms of the Creative
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childhood weight gain [3-5] and an increased risk of
Type 2 diabetes in childhood [2,5].
Children who develop childhood Type 2 diabetes also
have an increased rate of hypertension. In one surveil-
lance report there was a six fold increase in risk, and
nearly a quarter of children with Type 2 DM were found
to have hypertension [6]. A combination of hypertension
and childhood Type 2 diabetes has important implica-
tions for ongoing adult cardiovascular health.
Although very low birth weight and premature infants
are reported to demonstrate elevated blood pressure
(BP) measurements in the preschool time period [7,8]
there are limited published BP data for the pre-school
offspring of women with GDM [9]. Accordingly we
aimed to determine the systolic and diastolic BP at two
years of age in a cohort of children exposed to GDM
using data from the MiG trial of metformin use in GDM
[10]. The whole group data will assist with determining
the contribution of GDM to child health. Although it is
recognized that there is still insufficient information on
the childhood effects of maternal treatment of GDM by
tight control compared to minimal intervention [1], it
was considered of interest to study the effect, if any, of
maternal treatment type. Thus a secondary aim was to
analyze these data by randomization of treatment to in-
sulin or metformin. Body composition and anthropo-
metric measurements for this cohort have previously
been reported, with the children exposed to metformin
having larger measures of subcutaneous body fat but
similar total body fat to those children whose mother re-
ceived insulin [11].
Methods
The original MiG trial methods have been previously re-
ported [10,11]. Women with GDM, whose hypergly-
caemia had not responded to lifestyle measures, were
randomly assigned at 20 to 33 weeks of gestation to
open treatment with metformin (with supplemental in-
sulin if required) or to insulin and a combination of neo-
natal and maternal outcomes were studied. The details
of arrangements for follow up and body composition at
2 years of age have also been reported [11].
Women who had consented to further follow-up of
their child were telephoned around the child’s second
birthday to invite ongoing participation and assessment.
In Auckland, a home visit was arranged and simple an-
thropometry measurements of the mother and child
were made. A follow-up appointment was made within 1
to 2 weeks of the home visit to attend the Liggins Insti-
tute, University of Auckland, for the child to have a
physical examination, including formal blood pressure
measurement. In Adelaide, all but two of the follow-up
assessments were performed in hospital at an outpatientresearch clinic, when formal blood pressure and an-
thropometric measurements were made. Blood samples
were drawn as possible, and Bayley assessment and body
composition studies were also performed, either at the
same or a separate occasion.
This follow-up study had ethical approval from the
Northern A Health and Disability Ethics Committee in
Auckland and the Women's and Children's Hospital Net-
work Human Research Ethics Committee in Adelaide.
Written informed consent was again obtained for each par-
ticipant. It ran from November 2004 to February 2008.
The study was registered under the Australian New
Zealand Clinical Trials Registry (ACTRN12605000
311651).
BP was measured by a researcher at a morning follow
up appointment using a Dinamap XL vital-signs monitor
(Critikon, Tampa, FL). Measurements were made from
the right arm using an appropriately sized cuff.
Data are presented as mean (SD) unless not normally
distributed, when median (range) is used. Continuous
data were analysed using stepwise linear regression. An
initial model was obtained by fitting outcome to all co-
variates: gestation age, ethnicity, height, weight, waist,
hip, chest and arm measurements. Factors were then re-
moved stepwise in descending order of P-values when-
ever they were found to be non-significant (P < 0.05),
yielding the final model. Categorical data were analysed
using Chi square and Fischer’s exact test as appropriate.
Box and whisker plots have been used to illustrate the
data distribution.
Results
Blood pressure measurements were obtained in 170
(53%) of the total children (Figure 1) who attended for
assessment at two years. The group included 89 girls
(52.3%) and 81 boys (47.7%) at a median (range) age of
29 (22–38) months corrected gestational age. In the ori-
ginal MiG trial, the mother had been allocated to insulin
for 87 (51.2%) of these children and to metformin for
the remaining 83 (48.8%) children. Although over 50
percent of the group were of European ethnicity, there
was a spread of ethnicity including significant numbers
of Pacific and Indian children (Table 1).
There were no differences in distribution of treatment
by ethnicity despite this being a subgroup of the ori-
ginal trial participants. At the time of assessment the
mean (SD) weight and height was 13.8 (2.0) kg and 90.0
(4.2) cm for the whole study group. There were no dif-
ferences in weight at 13.7 (1.9) kg versus 14.0 (2.0) kg
and height at 90.5 (4.7) versus 90.4 (5.1) cm for insulin
and metformin groups respectively. Sex was also
equally distributed between the treatment groups with
41 males (47.1%) in insulin group and 40 males (48.2%)
in the metformin group.
Figure 1 Flow diagram of follow up from original trial recruitment.
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children (mean 2.9 per child). For the whole group the
mean (SD) systolic pressure was 90.9 (9.9) mmHg and
mean (SD) diastolic pressure was 55.7 (8.1) mmHg. Dis-
tribution of systolic and diastolic pressures divided by
treatment group and gender are shown in the figure
(Figure 2).
In the regression model, height and weight were only
two significant factors associated with the systolic blood
pressure. For each additional kg the systolic blood pres-
sure increased by 1.0 mmHg (CI 0.3 to 1.7, P-value –
0.003). For each additional cm of height the systolic
blood pressure increased by 0.42 mmHg (CI 0.1 to 0.7,Table 1 Maternal Ethnicity by Initial Treatment Allocation
Ethnicity mother Insulin-treated Metformin-treated Total (%)
European 44 50 94 (55.3)
Chinese 6 6 12 (7.1)
Indian 13 7 20 (11.8)
Maori 1 4 5 (2.9)
Other 4 2 6 (3.5)
Other Asian 6 4 10 (5.9)
Polynesian 13 10 23 (13.5)
Total 87 83 170 (100)P-value-0.003). No difference was found between the
metformin and the insulin arms.Discussion
In this study we report data on blood pressure obtained
at approximately two years of age in a substantial cohort
of children whose mothers had received treatment dur-
ing their pregnancy for GDM. These novel data are re-
assuring for the group as a whole with a mean systolic
pressure of 90.9 mmHg and mean diastolic pressure of
55.7 mmHg, which compares favorably with published
norms for children not exposed to GDM [8,12]. Van
Houten [12] reported mean systolic and diastolic BP of
101 and 62 mmHg respectively in boys and 102 and
63 mmHg respectively in girls at a mean age of
25.1 months in a study of well children from the
Netherlands. The mean weights of these Dutch children
were 12.85 Kg and 12.45 Kg for males and females re-
spectively. Our study children were slightly older at
29 months and had a slightly heavier mean weight at
14 kg but the mean length was very similar [89.6 cm and
88.7 versus 90 cm]. In another study of Australian
norms, from a population reported to comprise approxi-
mately 90 percent Caucasian children [13], the 50th cen-
tile for systolic/diastolic blood pressure was 99/51 with
5th centile 87/39 and 95th 114/64 mmHg at 3 years.
In a study of infants from the USA who were exposed
to GDM, the mean systolic BP at 3 years of age was re-
ported to be 3.2 mmHg higher than that in controls
born to normoglycaemic mothers after adjustment for
sex age and measurement condition. In this study popu-
lation, of whom 73% were born to mothers described as
white American, the mean systolic BP was 92 mmHg,
which is similar to the US 50th centile [9]. A recent sys-
tematic review [14] has reported increased systolic BP
following exposure to diabetes in-utero but no effect on
diastolic BP. However, there were important differences
in type of maternal diabetes, sex and age at follow up
that require further investigation. Two years of age is an
early time point to observe BP, so the MiG cohort are
currently being followed up and having their BP mea-
sured in later childhood, with plans to continue surveil-
lance into adolescence and adulthood. In a very small
group of 25 children followed up following in utero met-
formin exposure given for maternal polycystic ovarian
syndrome a small but significant increase in systolic
blood pressure was reported [15]. The authors correctly
pointed out that, given the small numbers in the study,
further research was required before conclusions could
be made. On univariate analysis of our study data, there
was a small difference in raw systolic blood pressure
(mean 89.8 mmHg versus 92.2 mmHg) between the





















Figure 2 Box and whisker plot showing raw systolic and diastolic blood pressure a two years of age divided by treatment arm (a) and sex (b).
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height, weight and arm measurements.
The methodology for the study is robust in that the
BP data were prospectively collected by dedicated re-
searchers, all highly motivated and who had time to set-
tle the child and achieve a co-operative state prior to
performing the measurements. Attempts were made to
collect more than one recording. In addition, treatment
allocation was subject to the usual care involved in a
randomized controlled trial.
The two study limitations of note were first that, as
mentioned above, two years of age is early in childhood
to detect significant differences in cardiovascular health,
and second, that BP measurement was only obtainedfrom the subgroup of the offspring (53%) who returned
to the follow up appointment. The rate of successfully
measuring blood pressure in our cohort is comparable
with that published by Van Houten et al. [12], who re-
ported successful measurement in 63 percent of 836
children at two years of age. However, it represents an
overall follow up of just under 30 percent of the 577
children potentially available from the original MiG trial
[10]. A low follow up rate could introduce variation
from the original study, so it was important to examine
the characteristics of the group. Except for a lower pro-
portion of Pacific Island ethnicity, however, this group
were not different in baseline characteristics from those
in the initial trial [10].
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It is recognized that adverse perinatal events, including
prematurity, may be associated with elevated blood pres-
sure in childhood [7]. An increase in childhood systolic,
but not diastolic, blood pressure has been reported in
offspring following maternal diabetes in pregnancy [14].
The offspring of pregnant women who develop GDM
are also at an increased risk of developing type 2 dia-
betes. In this follow up of offspring from women with
GDM studied in the MiG trial the systolic blood pres-
sure was comparable with reported norms and showed
no difference between treatment arms. Although it is
important to continue to assess the cardiovascular status
of this group as they proceed through childhood, the
current study provides important novel data at two years
of age for children exposed to the in utero effects of
GDM.
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